Anixa Biosciences falls on phase 1 data for breast cancer vaccine
Source: SeekingAlpha
2025-12-12 11:32:42 ET
More on Anixa Biosciences
- Anixa Biosciences, Inc. (ANIX) Discusses Differentiated CAR-T Therapy and Breast Cancer Vaccine Clinical Programs Transcript
- Anixa Biosciences: Hard To Justify The Market's Optimism With An Upcoming Phase 1 Readout
- Anixa Biosciences executes data transfer deal with Cleveland Clinic
- Seeking Alpha’s Quant Rating on Anixa Biosciences
- Historical earnings data for Anixa Biosciences
Read the full article on Seeking Alpha
For further details see:
Anixa Biosciences falls on phase 1 data for breast cancer vaccine
Anixa Biosciences Inc.
NASDAQ: ANIX
ANIX Trading
3.78% G/L:
$2.9682 Last:
44,719 Volume:
$2.88 Open:
ANIX Latest News
March 09, 2026 08:30:00 am
Anixa Biosciences Receives Notice of Allowance from Korean Ministry of Intellectual Property (MOIP) for Patent Covering Breast Cancer Vaccine Technology
March 02, 2026 09:10:00 am
Anixa Biosciences to Host 2026 Annual Meeting of Stockholders and Provide Corporate Update Highlighting Recent Clinical and Regulatory Progress
February 25, 2026 01:45:00 pm
BioMedNewsBreaks - Anixa Biosciences, Inc. (NASDAQ: ANIX) CAR-T Co-Inventor To Keynote SCTR 2026 Retreat
ANIX Stock Data
$99,470,925
24,567,316
0.4%
30
N/A
Biotechnology & Life Sciences
Healthcare
US
San Jose
